John F. Seymour, MBBS, FRACP, PhD

Articles

Dr Seymour on the Role of Mutational Profiling in CLL

September 6th 2024

John Seymour, MBBS, FRACP, PhD, discusses the role of genetic profiling in the treatment of chronic lymphocytic leukemia.

Dr Seymour on Patient Subsets That May Benefit From Curative FCR in CLL

September 21st 2023

John Seymour, MBBS, FRACP, PhD, discusses the characteristics of patient subgroups with chronic lymphocytic leukemia who may benefit from curative treatment with fludarabine, cyclophosphamide, and rituximab.

Dr Seymour on the Importance of Targeted Therapy in CLL

September 13th 2023

John Seymour, MBBS, FRACP, PhD, discusses the importance of targeted therapy in patients with chronic lymphocytic leukemia.

Dr Seymour on the Curative Potential for FCR Treatment in CLL

September 11th 2023

John Seymour, MBBS, FRACP, PhD, discusses the curative potential of fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia.

Dr. Seymour on the Safety of Acalabrutinib Vs Ibrutinib in Relapsed/Refractory CLL

January 10th 2022

John F. Seymour, discusses the findings from a post-hoc analysis of the phase 3 ELEVATE-RR trial examining the adverse effects experienced with the BTK inhibitors acalabrutinib and ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia.

Dr. Seymour Discusses the Results of the PRIMA Study

April 28th 2014

John F. Seymour, MBBS, FRACP, PhD, from the Department of Hematology at the Peter MacCallum Cancer Centre in East Melbourne, Australia, discusses the results of the PRIMA study, which evaluated the benefit of maintenance therapy with rituximab after induction of response with chemotherapy plus rituximab in comparison with no maintenance therapy in patients with advanced follicular lymphoma.

Dr. Seymour on the Efficacy of ABT-199 in High-Risk CLL

December 8th 2013

John F. Seymour, MBBS, FRACP, PhD, discusses the efficacy of single-agent ABT-199 (GDC-0199), a novel Bcl-2 inhibitor, in high-risk relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.